Valeant Upgraded To Overweight From Equal Weight At Barclays

Image result for Valeant

Barclays analyst Douglas Tsao upgraded Valeant Pharmaceuticals (VRX) to Overweight from Equal Weight and raised his price target for the shares to $29 from $20. The drugmaker closed yesterday up $1.59 to $23.59.

Valeant's business has hit an inflection point with its existing business stabilizing, which offers a foundation for the company to enjoy growth driven by upcoming product launches, Tsao tells investors in a research note.

While none of the launches are likely to be "blockbusters," with base business performing well and impact of loss-of-exclusivities lessening after this year, the "threshold for success has come down meaningfully," Tsao contends.

Disclaimer: TheFly's news is intended for informational purposes only and does not claim to be actionable for investment decisions. Read more at

How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.


Leave a comment to automatically be entered into our contest to win a free Echo Show.